Tuesday - May 13, 2025
Portage, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2024 Annual Meeting of Shareholders is scheduled as follows:
Thursday, May 9, 2024 – 9:30 a.m. Eastern Time
The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Corporation Annual Meeting" when greeted by the operator.
A recording of the annual meeting will also be available from 10:30 a.m., Eastern Time, on Friday, May 10, 2024 at www.virtualshareholdermeeting.com/SYK2024 until the definitive proxy statement for our 2025 Annual Meeting of Shareholders is filed with the United States Securities and Exchange Commission.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com
Last Trade: | US$387.53 |
Daily Change: | -0.55 -0.14 |
Daily Volume: | 796,731 |
Market Cap: | US$147.730B |
May 01, 2025 March 04, 2025 March 03, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load